|  | Cancer | Lymphoma

Ependymoma: Symptoms, Molecular Classification, Treatment, and Prognosis

Ependymomas are glial tumors arising from ependymal cells lining the cerebral ventricles and spinal cord central canal. They occur across the lifespan with bimodal peaks: young children (<5 years, posterior fossa) and adults 30-40 years (spinal > supratentorial). Molecular subgroups now define prognosis and therapy more than histology alone.

Molecular Classification (WHO CNS5)

Clinical Presentation

  • Intracranial (PF/ST): Headache (morning, positional), nausea/vomiting (raised ICP), ataxia, cranial nerve palsies (VI, VII), seizures (ST), cognitive/personality changes.
  • Spinal: Back pain (nocturnal, radicular), sensory loss, weakness, bowel/bladder dysfunction, Lhermitte's sign.

Risk Factors

  • Age (bimodal), slight male predominance.
  • Prior cranial/spinal radiation (therapy-related, latency 10-20 yrs).
  • Genetic syndromes: NF2 (spinal), Turcot (APC/MUTYH).

Treatment Paradigm

1. Maximal Safe Resection — The Strongest Prognostic Factor

  • Gross Total Resection (GTR): 5-yr PFS 70-80% (PF), >90% (spinal).
  • Subtotal/biopsy only: Significantly worse.
  • Neuromonitoring (MEPs, SSEPs, cranial nerve EMG) essential.

2. Radiotherapy

  • PF-EPN-A / ST-EPN-RELA / Grade 3: Post-op focal RT 54-59.4 Gy standard.
  • PF-EPN-B / Grade 2 GTR: Observation vs. RT debated; many defer.
  • Spinal: RT for residual/recurrent, Grade 3, or MYCN-amp.
  • Proton therapy: Reduces dose to cochlea (hearing), hypothalamus/pituitary (endocrine), temporal lobes (neurocognition), heart/lungs (spinal). Preferred for children.

3. Chemotherapy

  • Role less defined than medulloblastoma.
  • Used for: Very young children (<3-4 yr) to defer RT; recurrent/progressive disease; metastatic.
  • Regimens: Platinum-based (cisplatin/etoposide/cyclophosphamide), temozolomide, high-dose chemo + autologous stem cell rescue (experimental).

Prognosis & Surveillance

  • 5-yr OS: ~65-85% overall (varies by location, grade, molecular group, resection extent).
  • Spinal > Supratentorial > Posterior Fossa (PF-EPN-A worst).
  • Late recurrence possible (>10 yrs) — lifelong surveillance.
  • Late effects: Neurocognitive (RT), endocrine (hypothalamic-pituitary), hearing (cisplatin/RT), secondary malignancies.

Ependymoma management hinges on maximal safe surgery, molecularly-informed radiation decisions, and lifelong multidisciplinary follow-up for cure and quality of survival.

Lymphoma - Related Articles

Health Sciences © https://www.222health.com

LocationMolecular GroupKey Features
Posterior Fossa (PF)PF-EPN-A (H3K27me3 loss / EZHIP overexpression)Infants/young children, balanced genome, poor prognosis
Posterior FossaPF-EPN-B (intact H3K27me3)Older children/adults, 1q gain common, better prognosis
Supratentorial (ST)ST-EPN-RELA (C11orf95-RELA fusion)Children/young adults, ~70% ST, aggressive
SupratentorialST-EPN-YAP1 (YAP1 fusions)Infants, better prognosis
SpinalSP-EPN (MYCN amplification in subset)Adults, MYCN-amp = worse; otherwise excellent prognosis